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doi:10.1Objective: Infections acquired by children during extracorporeal membrane oxygenation (ECMO) increase
mortality. Our aim was to evaluate the effectiveness of prophylactic fluconazole on the incidence of fungal
infections and to assess whether hospital-acquired fungal infection is associated with increased in-hospital mor-
tality in pediatric cardiac patients requiring ECMO.
Methods:We retrospectively reviewed a prospectively maintained database and collected data on all hospital-
acquired infections in patients supported for cardiac indications at a tertiary children’s hospital from 1989 to
2008.
Results: ECMO was deployed 801 times in 767 patients. After exclusion criteria were applied, 261 pediatric
patients supported for cardiac indications were studied. Fungal infection (blood, urine, or surgical site) occurred
in 12% (31/261) of patients, 9 (7%) of 127 patients receiving fluconazole prophylaxis versus 22 (16.4%) of 134
without antifungal prophylaxis (P¼ .02). Using a multivariable logistic regression model, the absence of fluco-
nazole prophylaxis was associated with an increased risk of fungal infection (odds ratio [OR] ¼ 2.8; 95% con-
fidence intervals [CI], 1.2, 6.7; P ¼ .016). In a multivariable logistic regression model for in-hospital mortality,
the presence of fungal infection was associated with increased odds (OR¼ 3.8; 95%CI, 1.5, 9.6;P¼ .005) of in-
hospital mortality among cardiac patients requiring ECMO, and the absence of antifungal prophylaxis showed
a trend toward the same (OR ¼ 1.6; 95% CI, 0.96, 2.8; P ¼ .072).
Conclusions: Children with cardiac disease supported with ECMO who acquire fungal infections have in-
creased mortality. Routine fluconazole prophylaxis is associated with lower rates of fungal infections in these
patients. (J Thorac Cardiovasc Surg 2012;143:689-95)P
MExtracorporeal membrane oxygenation (ECMO) is used to
support cardiopulmonary function in patients with refrac-
tory but potentially reversible cardiac and/or respiratory
failure. The risk of hospital-acquired infection (HAI) is sub-
stantial in both pediatric and adult patients supported with
ECMO, including patients supported with ECMO after
cardiotomy.1-11 In a 1996 review of data from the
Extracorporeal Life Support Organization (ELSO)
registry, Douglass, Keenan, and Purhoit9 highlighted the in-
creased risk of hospital mortality in pediatric ECMO pa-
tients in whom infections developed. This increased risk
has been documented in both retrospective and prospective
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The Journal of Thoracic and Cainfections were uncommon (0.6%) but were associated
with higher hospital mortality rates than were bacterial
infections.9 HAIs, particularly fungal infections, are an im-
portant source of added morbidity and mortality in critically
ill patients supported with ECMO.1,2,9,12,13 In a recent study
of HAI in more than 20,000 ECMO cases from the ELSO
registry, Candida species were the second most common
organism isolated.14
Two previous studies from our institution have examined
HAI during ECMO support.1,2 In a retrospective analysis of
109 patients, Schutze and Heulitt1 demonstrated that infec-
tions developed during ECMO in 16% of patients, of which
50% were due to fungal organisms. In 2001, O’Neil and
colleagues2 re-examined the incidence and types of infec-
tions occurring during ECMO at our institution and found
a 26% rate of HAI, with 38% being caused by fungal or-
ganisms. Urinary tract infections caused by fungal organ-
isms were noted to be particularly prevalent. The first of
these studies included 37 (34%) of 109 and the second 75
(53%) of 141 (53%) pediatric cardiac patients requiring
ECMO.1,2 As a result of the high incidence of fungal
infection reported in these studies, a practice change was
instituted to encourage the use of prophylactic fluconazole
for pediatric patients supported with ECMO at our
institution, particularly cardiac patients requiring ECMO.
Although fluconazole has been rarely associated withrdiovascular Surgery c Volume 143, Number 3 689
Abbreviations and Acronyms
CI ¼ confidence intervals
ECMO ¼ extracorporeal membrane
oxygenation
ELSO ¼ Extracorporeal Life Support
Organization
HAI ¼ hospital-acquired infection
IQR ¼ interquartile range
OR ¼ odds ratio
RACHS-1 ¼ Risk Adjustment for Congenital
Heart Surgery
ROC ¼ receiver operating characteristic
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Mhepatotoxicity and cholestasis, large studies of prophylaxis
with fluconazole to prevent invasive fungal infections have
found it to be both safe and efficacious in such populations
as premature and low-birth-weight infants and immuno-
compromised patients.15-17 The effectiveness of this
practice has not been previously evaluated in pediatric
patients supported with ECMO. The primary aim of this
study was to evaluate the effect of prophylactic
fluconazole therapy on the incidence of fungal infections
in pediatric cardiac patients supported with ECMO. A
secondary aim was to evaluate the impact of
extrapulmonary fungal HAI on in-hospital mortality in
this population.PATIENTS AND METHODS
Setting and Study Population
This study was approved by the Institutional Review Board at the Uni-
versity of Arkansas forMedical Sciences, and the requirement for informed
consent was waived. This study was conducted at Arkansas Children’s
Hospital, a 316-bed free-standing tertiary children’s hospital in Little
Rock, Arkansas. We performed a retrospective review of an institutional
ECMO database and identified 801 ECMO deployments provided to 767
patients from March 1989 through July 2008. We excluded all patients
19 years of age or older at the initiation of ECMO support, patients with
ECMO duration of less than 48 hours, patients with incomplete microbio-
logic data, and patients supported with ECMO for respiratory failure
(Figure 1). We also excluded patients transported to other institutions by
our mobile ECMO team. After exclusion criteria were applied, 261 cardiac
patients supported by ECMO were studied.
Data Collection
Data were obtained by reviewing a prospectively maintained institu-
tional ECMO database and hospital medical records, including physician
orders, daily progress notes, laboratory records, pharmacy records, and
daily ECMO records maintained by ECMO specialists and coordinators.
Data collected included patient demographics, diagnoses at initiation of
ECMO support, duration of ECMO, use of fluconazole prophylaxis, any
positive culture between the initiation of ECMO and 7 days after
ECMO, broad-spectrum antibiotic use during ECMO support, operative
status (postoperative/bridged to transplant, postoperative/not bridged to
transplant, not postoperative/bridged to transplant, not postoperative/not
bridged to transplant, or cardiac transplant), Risk Adjustment for690 The Journal of Thoracic and Cardiovascular SurgCongenital Heart Surgery (RACHS-1) score,18 and survival to hospital dis-
charge. For patients with more than 1 episode of ECMO support during
a hospitalization, only the first episode was analyzed.
Study Definitions
For purposes of this study, the patient was considered to have re-
ceived fluconazole prophylaxis if no pre-existing fungal infection was
identified and if intravenous fluconazole therapy was initiated within
the first 24 hours of ECMO support. Prophylactic fluconazole therapy
has been a component of the standard ECMO order set at our institution
since the late 1990s, but with its use left at the discretion of the pa-
tient’s physician. Intravenous fluconazole is administered at a dose of
6 mg/kg once daily, with dosing decreased 50% for significant renal
impairment. Prophylactic fluconazole treatment is discontinued at the
time of discontinuation of ECMO support unless the patient has a docu-
mented fungal infection requiring further treatment. Routine surveil-
lance cultures of blood, urine, tracheal secretions, and surgical sites
are obtained daily for all pediatric patients supported with ECMO at
our institution.
A positive culture was defined as recovery of an organism from blood,
urine, or surgical site not identified before ECMO support but collected 48
hours or more after hospital admission. Positive cultures within the first 48
hours of hospitalization were excluded to prevent inclusion of patients with
community-acquired infections. A HAI was defined as an infection that
was not present, nor an extension of an infection present, on admission
to the hospital.19 All HAIs while the patient was receiving ECMO support
or within 7 days after ECMO were recorded.
Microbiologic records were screened for the following fungal organ-
isms: Candida spp (albicans, tropicalis, glabrata, parapsilosis, krusei,
and lusitaniae), Aspergillus spp (fumigatus, flavus, and niger), Blastomy-
ces, Coccidioides, Histoplasma, Cryptococcus neoformans, and Tricho-
sporon spp (belgelii and cutaneum). Extrapulmonary fungal HAIs (from
blood, urine, or surgical sites) were considered a clinically significant out-
come for analysis. Positive endotracheal cultures for fungal organisms
were not analyzed for the following reasons: (1) the technique for obtaining
pulmonary secretions for culture at our institution was not consistent dur-
ing the study period or (2) the difficulty in delineating fungal colonization
of an endotracheal tube from a true ventilator-associated pneumonia in pe-
diatric patients.20
We recorded the use of extended-spectrum penicillins and third- and
fourth-generation cephalosporins before the first positive culture. Once
a positive culturewas identified, pharmacy records were examined to deter-
mine whether these broad-spectrum antibiotics were used before the infec-
tion and, if so, the duration of therapy.
Statistical Analysis
Continuous variables were summarized using the median and inter-
quartile range (IQR). The IQR is the interval from the first quartile to
the third quartile (25th-75th percentile). Discrete variables were summa-
rized as frequency and percentage. Characteristics of patients were com-
pared by treatment group (prophylactic fluconazole versus control) using
the Wilcoxon rank sum tests for continuous variables and Pearson c2
tests for categorical variables (Table 1). Multivariable logistic regression
analysis was used to evaluate the association between the candidate
independent variables and the outcomes fungal infection and death
during the hospitalization. The independent candidate predictor vari-
ables in the model included ECMO duration (indicator for>10 days),
age at initiation of ECMO support (indicator for<30 days), treatment
with prophylactic fluconazole, operative status (5 categories: postopera-
tive/bridged to transplant, postoperative/not bridged to transplant, not
postoperative/bridged to transplant, not postoperative/not bridged to
transplant, cardiac transplant), and history of delayed sternal closure.
The model for hospital mortality was fit with and without an indicator
variable for fungal infection. The area under the receiver operatingery c March 2012
FIGURE 1. Flow chart showing inclusion and exclusion criteria. ECMO,
Extracorporeal oxygenation.
Gardner et al Perioperative Managementcharacteristic (ROC) curve was used to quantify model discrimination.
A validated area under the ROC was calculated using 100 bootstrap
samples. The validated ROC estimates the performance of the model
on other data sets. The Hosmer-Lemeshow goodness-of-fit test was
used to evaluate model calibration. Stata/MP11 (Stata Corporation, Col-
lege Station, Tex) and the Harrell regression modeling strategies pack-
age in R were used for the analyses.TABLE 1. Demographic comparison by fungal infection
Characteristics No
No. of patients 230
Male, n (%) 129 (56%)
Age, mo
Median (IQR) 2 (0.03, 14)
<30 days, n (%) 104 (45%)
Duration of ECMO, h
Median (IQR) 168 (95, 263)
240 h, n (%) 167 (29%)
Mode of ECMO
Venoarterial, n (%) 224 (97%)
Operative status, n (%)
Postoperative, bridged to transplant 15 (7%)
Postoperative, not bridged to transplant 120 (52%)
Not postoperative, bridged to transplant 32 (14%)
Not postoperative, not bridged to transplant 52 (23%)
Cardiac transplant 11 (5%)
Delayed sternal closure, n (%) 130 (57%)
Antifungal prophylaxis, n (%) 118 (51%)
Death before discharge, n (%) 101 (44%)
ECMO era, n (%)
Started on ECMO 1989-2001 99 (43%)
Started on ECMO 2002-2008 131 (57%)
P values are based in the c2 test for categorical variables or the Wilcoxon rank sum test
ECMO, extracorporeal membrane oxygenation.
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Patient Characteristics
A total of 767 patients underwent 801 ECMO deploy-
ments for respiratory or cardiac support from 1989 to
2008. Of the 801 cases, 540 were excluded, leaving 261 pa-
tients supported with ECMO for cardiac indications for
analysis (Figure 1). A description of the study sample is
shown in Table 2.
Fungal Infection
The incidence of extrapulmonary fungal HAI in pediatric
cardiac patients requiring ECMO was 12% (31/261). Sites
for fungal infection included surgical site (5%, 13/261),
urine (5%, 15/261), and bloodstream 3.4% (9/261). Extrap-
ulmonary fungal HAI occurred in 7% (9/127) of patients re-
ceiving fluconazole prophylaxis versus 16.4% (22/134)
without antifungal prophylaxis (P ¼ .02) (Table 1). Funge-
mia occurred in 2.4% (3/127) of patients receiving flucona-
zole prophylaxis versus 4.5% (6/134) of patients not
receiving antifungal prophylaxis (P ¼ not significant).
Eighty-seven percent (27/31) of patients had positive fungal
cultures frommore than 1 site (blood, urine, or surgical site).
Candida species accounted for 29 (94%) of 31 positive fun-
gal cultures, with the remainder being Aspergillus species.
Longer duration of ECMO support was associated with
fungal HAI. Median (IQR) ECMO duration (hours) was
168 (95, 263) in the group with negative fungal culturesFungal infection
Yes Total P value
31 261
14 (45%) 143 (55%) .25
2 (0.4, 18) 2 (0.03, 14) .36
13 (42%) 117 (45%) .73
236 (180, 336) 175 (108, 272) .001
15 (48%) 82 (31%) .03
31 (100%) 255 (98%) .36
.80
1 (3%) 16 (6%)
19 (61%) 139 (53%)
5 (16%) 37 (14%)
5 (16%) 57 (22%)
1 (3%) 12 (5%)
19 (61%) 149 (57%) .61
9 (29%) 127 (49%) .02
24 (77%) 125 (48%) <.001
.001
23 (74%) 122 (47%)
8 (26%) 139 (53%)
for continuous variables. IQR, Interquartile range (25th percentile, 75th percentile);
rdiovascular Surgery c Volume 143, Number 3 691
P
M
TABLE 2. Description of the study sample by prophylactic antifungal therapy
Characteristics
Prophylactic antifungal therapy
No Yes Total P value
No. of patients 134 127 261
Male, n (%) 67 (50%) 76 (60%) 143 (55%) .11
Age, mo
Median (IQR) 1.4 (0.033, 17) 2.4 (0.033, 14) 2.0 (0.033,14) .76
<30 days, n (%) 61 (46%) 56 (44%) 117 (45%) .82
Duration of ECMO, h
Median (IQR) 171 (111, 257) 177 (100, 286) 175 (108, 272) .74
240 h, n (%) 37 (28%) 45 (35%) 82 (31%) .17
Mode of ECMO
Venoarterial, n (%) 224 (97%) 31 (100%) 255 (98%) .36
Operative status, n (%) .12
Postoperative, bridged to transplant 8 (6%) 8 (6%) 16 (6%)
Postoperative, not bridged to transplant 78 (58%) 61 (48%) 139 (53%)
Not postoperative, bridged to transplant 12 (9%) 25 (20%) 37 (14%)
Not postoperative, not bridged to transplant 31 (23%) 26 (20%) 57 (22%)
Cardiac transplant 5 (4%) 7 (6%) 12 (5%)
RACHS-1 classification, n (%) .58
Not applicable 49 (37%) 59 (46%) 108 (41%)
1 0 (0%) 1 (1%) 1 (0%)
2 6 (4%) 4 (3%) 10 (4%)
3 32 (24%) 26 (20%) 58 (22%)
4 24 (18%) 16 (13%) 40 (15%)
5 2 (1%) 1 (%1) 3 (1%)
6 21 (16%) 20 (16%) 41 (16%)
Delayed sternal closure, n (%) 81 (60%) 68 (54%) 149 (57%) .26
Death before discharge, n (%) 73 (54%) 52 (41%) 125 (48%) .029
ECMO era, n (%) < .001
Started on ECMO 1989-2001 113 (84%) 9 (7%) 122 (47%)
Started on ECMO 2002-2008 21 (16%) 118 (93%) 139 (53%)
P values based on c2 tests for categorical variables or the Wilcoxon rank sum test for continuous variables. IQR, Interquartile range (25th percentile, 75th percentile);
ECMO, extracorporeal membrane oxygenation; RACHS-1, Risk Adjustment for Congenital Heart Surgery.
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culture developed (P<.001). Of those patients with a fungal
infection, 35% (11/31) had been previously treated with
broad-spectrum antibiotics; 5 with third- or fourth-
generation cephalosporins, 4 with extended-spectrum peni-
cillins, and 2 with both.
Fluconazole Therapy and Risk of Fungal Infection
Patients who received prophylactic fluconazolewere sim-
ilar to controls onbaselinemeasures (Table 2). In amultivari-
able logistic regressionmodel to predict fungal infection, the
absence of fluconazole prophylaxis was associated with an
increased risk of fungal infection (odds ratio [OR] ¼ 2.8;
95% confidence intervals [CI] 1.2, 6.7; P ¼ .016)
(Table 3). Neither neonatal age nor delayed sternal closure
was associated with a risk of fungal infection in this model.
Fungal Infection and In-Hospital Mortality
Fungal infection was associated with increased mortality
in pediatric cardiac patients requiring ECMO. Of 31 pa-
tients with fungal infections, 24 (77%) did not survive to692 The Journal of Thoracic and Cardiovascular Surghospital discharge. With the same preselected, clinically
relevant variables, a multivariable logistic regression model
to predict in-hospital mortality demonstrated that a fungal
infection of blood, urine, or surgical site was associated
with an increased risk of in-hospital mortality (OR ¼ 3.8;
95% CI, 1.5, 9.6; P¼ .005). Absence of prophylactic fluco-
nazole use did not attain statistical significance in a model
also containing fungal infection (OR ¼ 1.6; 95% CI,
0.96, 2.8; P ¼ .07). Given that our model contains both
treatment with fluconazole and fungal infection, the effect
of fluconazole is mediated. In a model that omits fungal in-
fection, the absence of prophylactic fluconazole does attain
statistical significance (OR ¼ 1.8; 95% CI, 1.3, 3.1;
P¼ .023). Other variables in the model that were associated
with an increased risk of hospital mortality were neonatal
age, delayed sternal closure, and duration of ECMO support
greater than 10 days (Table 4).DISCUSSION
Our study is the first to examine the potential effective-
ness of prophylactic fluconazole to prevent fungal HAIsery c March 2012
TABLE 3. Multivariable logistic regression analysis for predictors of
fungal infection
Variables OR (95% CI)
P
value
Age<30 d 0.73 (0.32, 1.6) .44
Delayed sternal closure 0.9 (0.26, 3.4) .93
Operative status
Postoperative, bridged to transplant 1
Postoperative, not bridged to transplant 3.5 (0.41, 30) .25
Not postoperative, bridged to transplant 2.9 (0.23, 36) .41
Not postoperative, not bridged to transplant 2.4 (0.2, 30) .49
Cardiac transplant 2.1 (0.1, 42) .64
ECMO duration 240 h 2.8 (1.2, 6.5) .017
No antifungal prophylaxis 2.8 (1.2, 6.7) .016
Validated Area under the receiver operating characteristic is 0.59. Hosmer-Lemeshow
goodness-of-fit test, P ¼ .20, which is consistent with adequate fit. OR, Odds ratio;
CI, confidence interval; ECMO, extracorporeal membrane oxygenation.
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Min pediatric cardiac patients requiring ECMO. Prophylactic
fluconazole therapy was associated with a decreased inci-
dence of fungal infections from blood, urine, or surgical
sites, with patients not receiving prophylactic fluconazole
having a 2.8-fold increased risk of having a fungal HAI de-
velop. The use of prophylactic fluconazole was associated
with a strong trend toward decreased mortality. Develop-
ment of an extrapulmonary fungal HAI in pediatric cardiac
patients requiring ECMO was associated with a 3.8-fold in-
creased risk of in-hospital mortality. In addition to the use of
prophylactic fluconazole, the other clinical variable signif-
icantly associated with a lower risk of fungal infection was
a shorter duration of ECMO support.
To our knowledge, this is the first study to specifically de-
scribe the impact of extrapulmonary fungal HAI on in-
hospital mortality in this patient population. Previous
work at our institution identified major surgical procedures
before or during ECMO support, as well as transthoracic
ECMO cannulation and delayed sternal closure, as signifi-




Age<30 d 2.1 (1.2, 3.6)
Delayed sternal closure 1.7 (0.71, 3.9)
Operative status
Postoperative, bridged to transplant 1
Postoperative, not bridged to transplant 0.97 (0.33, 3.2)
Not postoperative, bridged to transplant 0.71 (0.17, 3)
Not postoperative, not bridged to transplant 1.1 (0.28, 4.6)
Cardiac transplant 1.2 (0.22, 6.8)
ECMO duration 240 h 2.6 (1.4, 4.9)
No antifungal prophylaxis 1.6 (0.96, 2.8)
Fungal infection (extrapulmonary) 3.8 (1.5, 9.6)
Validated area under the receiver operating characteristic is 0.68 for full model and 0.63 f
Lemeshow goodness-of-fit test. OR, Odds ratio; CI, confidence interval; ECMO, extracorp
The Journal of Thoracic and Cahowever, delayed sternal closure was not associated with an
increased rate of fungal HAI. This finding is somewhat sur-
prising and is in contrast to a recent study demonstrating
that a multidisciplinary team aimed at decreasing the rate
of health care–associated infections in patients requiring
ECMO was able to decrease the rate of sepsis in part by
decreasing the number of patients with open chest
cannulation.3
Patients receiving ECMO for cardiac support have sev-
eral reasons for being at increased risk of HAI in general
and from fungal infections specifically. Significant risk fac-
tors for any type of HAI include prolonged duration of
ECMO support—particularly in patients awaiting heart
transplantation, breach in anatomic host barrier—
pre-ECMO or post-ECMO, major surgical procedures,
transthoracic ECMO cannulation, and delayed sternal clo-
sure.2 Cardiac patients receiving ECMO support may also
have relative immunodeficiency: preoperative and postop-
erative absolute lymphopenia, cardiopulmonary bypass–
associated/induced monocyte deactivation, or genetic
syndromes that themselves predispose to immune defi-
ciency.21-24 One may speculate that a combination of
these factors might predispose cardiac patients requiring
ECMO to an increased risk of fungal infection and may
make them more likely to benefit from antifungal
prophylaxis while on ECMO support.
It is not surprising that a high percentage of patients (ap-
proximately one third) in whom a fungal infection devel-
oped during ECMO support had received broad-spectrum
antibiotics, specifically third- or fourth-generation cephalo-
sporins, before a fungal infection developed. Broad-
spectrum antibiotics such as these have been documented
in a variety of clinical situations to suppress normal flora and
promote overgrowth of fungal species, such asCandida spp.
Patients in whom fungal infections developed required
a longer duration of ECMO support than those who did
not, with a difference of approximately 1 day in the meanpredictors of in-hospital mortality
ressors Fungal infection omitted
P value OR (95% CI) P value
.01 2.0 (1.1, 3.4) .009
.25 1.6 (0.7, 3.8) .25
1
.95 1.2 (0.4, 3.7) .74
.64 0.83 (0.2, 3.4) .79
.85 1.3 (0.33, 5.1) .72
.81 1.4 (0.25, 7.7) .70
.004 2.9 (1.6, 5.4) .001
.07 1.8 (1.1, 3.1) .023
.005 Omitted
or model omitting fungal infection. Both models had adequate fit based on Hosmer-
oreal membrane oxygenation.
rdiovascular Surgery c Volume 143, Number 3 693
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Msupport time between the 2 groups. As would be expected,
a recent review of the ELSO registry showed that the risk of
any HAI increases with the duration of invasive support
such as ECMO.14Study Limitations
This study has several limitations. First, as a retrospective
study, it is subject to reporting bias and is also subject to po-
tential inconsistencies or gaps in data reviewed for the
study. As mentioned previously, approximately 300 poten-
tial study patients had to be excluded. The majority of pa-
tient exclusions were due to missing microbiologic data
from the era in which records were paper-based (before
1998). However, the remaining patients, with complete
data sets, represent a vast clinical experience at a large
ECMO center over a period of 2 decades. Another potential
limitation is the fact that prophylactic fluconazole use for
a patient requiring ECMO at our institution is at the discre-
tion of the attending physician. Thus, our study could poten-
tially be biased toward ‘‘sicker’’ patients receiving
fluconazole or from other biases in individual physician
practice. However, as noted in Table 2, 93% (118) of pedi-
atric cardiac patients on ECMO treated between 2002 and
2008 received antifungal prophylaxis and, again, the large
number of patients evaluated decreases the chance that
the primary findings are due to bias. The study did not
aim to specifically determine any ‘‘break points’’ in
ECMO duration as related to risk of fungal infection, but
such analysis may prove beneficial in the future for im-
proved targeting of prophylactic fluconazole use, particu-
larly in cardiac patients requiring ECMO. We also
recognize that numerous other factors may influence infec-
tion and mortality in patients requiring ECMO and that
many advances in the management of these patients have
occurred concurrently with the introduction of routine anti-
fungal prophylaxis at our institution. Quantifying and con-
trolling for all these variables is well beyond the scope of
our study. However, the significance of fungal HAI in pa-
tients requiring ECMO, and the high risk of mortality that
accompanies them, warrants our reporting of the data.CONCLUSIONS
In pediatric patients supported with ECMO for cardiac
indications, the presence of fungal infection increases the
risk of in-hospital mortality and routine fluconazole prophy-
laxis is associated with a decreased incidence of fungal in-
fections. The absence of prophylactic fluconazole therapy
was associated with increased mortality. To our knowledge,
this is the first study to demonstrate the effectiveness of an-
tifungal prophylaxis in children during ECMO for cardiac
support. Further prospective investigation into the use of an-
tifungal prophylaxis in patients requiring ECMO is
warranted.694 The Journal of Thoracic and Cardiovascular SurgWe gratefully acknowledge Dr Stephen M. Schexnayder and Dr
Todd G. Nick for their review of this manuscript and the dedica-
tion, hard work, and exceptional care provided daily by the
ECMO team at Arkansas Children’s Hospital.References
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